Reuters logo
BRIEF-Biomarin Pharmaceutical says European commission approves Brineura as first treatment for CLN2 disease
June 1, 2017 / 12:45 PM / 4 months ago

BRIEF-Biomarin Pharmaceutical says European commission approves Brineura as first treatment for CLN2 disease

June 1 (Reuters) - Biomarin Pharmaceutical Inc:

* European commission approves Brineura (cerliponase alfa), the first treatment for cln2 disease, a form of batten disease and ultra-rare brain disorder in children

* Biomarin Pharmaceutical Inc says dosing administration includes all ages from birth Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below